<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Geriatr Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">J Geriatr Cardiol</journal-id><journal-id journal-id-type="publisher-id">JGC</journal-id><journal-title-group><journal-title>Journal of Geriatric Cardiology : JGC</journal-title></journal-title-group><issn pub-type="ppub">1671-5411</issn><publisher><publisher-name>Science Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5253408</article-id><article-id pub-id-type="publisher-id">jgc-13-11-914</article-id><article-id pub-id-type="doi">10.11909/j.issn.1671-5411.2016.11.006</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kaplinsky</surname><given-names>Edgardo</given-names></name></contrib></contrib-group><aff id="aff1"><addr-line>Cardiology Unit, Medicine Department, Hospital Municipal de Badalona.Via Augusta Av. 9-13 (08911), Badalona, Spain</addr-line></aff><author-notes><corresp><bold>Correspondence to:</bold> Edgardo Kaplinsky, MD, Cardiology Unit, Medicine Department, Hospital Municipal de Badalona, Via Augusta Av. 9-13 (08911), Badalona, Spain. E-mail: <email>ejkaplinsky@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2016</year></pub-date><volume>13</volume><issue>11</issue><fpage>914</fpage><lpage>923</lpage><history><date date-type="received"><day>12</day><month>11</month><year>2016</year></date><date date-type="rev-recd"><day>13</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement>Institute of Geriatric Cardiology</copyright-statement><copyright-year>2016</copyright-year><license xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at high risk of morbidity and mortality. </plain></SENT>
<SENT sid="2" pm="."><plain>Sacubitril valsartan (previously known as LCZ696) is a new oral agent approved for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction. </plain></SENT>
<SENT sid="3" pm="."><plain>It is described as the first in class angiotensin receptor neprilysin inhibitor (ARNI) since it incorporates the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan. </plain></SENT>
<SENT sid="4" pm="."><plain>Neprilysin is an endopeptidase that breaks down several vasoactive peptides including natriuretic peptides (NPs), bradykinin, endothelin and angiotensin II (Ang-II). </plain></SENT>
<SENT sid="5" pm="."><plain>Therefore, a natural consequence of its inhibition is an increase of plasmatic levels of both, NPs and Ang-II (with opposite biological actions). </plain></SENT>
<SENT sid="6" pm="."><plain>So, a combined inhibition of these both systems (Sacubitril / valsartan) may enhance the benefits of NPs effects in HF (natriuresis, diuresis, etc) while Ang-II receptor is inhibited (reducing vasoconstriction and aldosterone release). </plain></SENT>
<SENT sid="7" pm="."><plain>In a large clinical trial (PARADIGM-HF with 8442 patients), this new agent was found to significantly reduce cardiovascular and all cause mortality as well as hospitalizations due to HF (compared to enalapril). </plain></SENT>
<SENT sid="8" pm="."><plain>This manuscript reviews clinical evidence for sacubitril valsartan, dosing and cautions, future directions and its considered place in the therapy of HF with reduced ejection fraction. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>Heart failure</kwd><kwd>LCZ696</kwd><kwd>Neprilysin</kwd><kwd>PARADIGM-HF</kwd><kwd>Sacubitril</kwd><kwd>Valsartan</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec id="s1"><label>1</label><title><text><SENT sid="9" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="10" pm="."><plain>Neurohumoral stimulation is the basis of the pathophysiology of heart failure (HF) so in consequence, a combined targeting of renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS) is indispensable to modify the evolution of HF with reduced ejection fraction (HF-rEF).[1] In this context, different landmark studies have shown an improvement of morbidity and mortality using angiotensin-converting enzyme inhibitors (ACEi), angiotensin-receptor blockers (ARBs), beta blockers and mineralocorticoid receptor antagonists (MRAs).[2] However and even with this regular “gold standard” therapy, HF is still the most common cause of hospitalization in elderly patients (≥ 65 years) and its mortality rates remain approximately 50% within five years of diagnosis.[3] </plain></SENT>
</text></p><p><text><SENT sid="11" pm="."><plain>Therefore, factors like this among other have driven the search and the necessity for new therapies in order to achieve a better outcome. </plain></SENT>
</text></p></sec></SecTag><sec id="s2"><label>2</label><title><text><SENT sid="12" pm="."><plain>Natriuretic peptides </plain></SENT>
</text></title><p><text><SENT sid="13" pm="."><plain>Natriuretic peptides (NPs) counter regulates the harmful effects of the up-regulation of RAAS and SNS which are capital in HF-rEF pathophysiology.[4] RAAS stimulation promotes vasoconstriction (via angiotensin II) and salt and water retention (via aldosterone) while SNS activation results in an increased heart rate, myocardial contractility and vasoconstriction. </plain></SENT>
<SENT sid="14" pm="."><plain>In addition, RAAS and SNS are strong inductors of myocardial hypertrophy and fibrosis, endothelial dysfunction and vascular remodeling. </plain></SENT>
</text></p><p><text><SENT sid="15" pm="."><plain>NPs are composed by a family of peptides that work maintaining water and salt homeostasis and thereby, compensating the deleterious effect of fluid overload present in HF patients. </plain></SENT>
<SENT sid="16" pm="."><plain>Three distinct NPs have been identified; atrial natriuretic peptide (ANP) which is produced by cardiac atrial cells (28 amino acids), brain natriuretic peptide (BNP) which is mostly from a myocardial cell origin (32 amino acids) and C-type natriuretic peptide (CNP) that principally has an endothelial origin (22 amino acids).[4] HF is the pathological condition in which the activation of these peptides is superlative and in this scenario, the increased cardiac wall stress (volume and/or pressure overload) is responsible of ANP and BNP synthesis and release. </plain></SENT>
<SENT sid="17" pm="."><plain>Their major biological actions (all beneficial in HF) include direct vasodilatation, natriuresis and diuresis, brought about by the intracellular augment of cyclic guanosine monophosphate (cGMP) that acts as second messenger.[5] CNP has a not completely understood autocrine and paracrine function (ossification process, vascular smooth, muscle proliferation, endothelial cell migration, etc).[4] </plain></SENT>
</text></p><p><text><SENT sid="18" pm="."><plain>In consequence and once the fact that NPS work to preserve homeostasis in HF, a novel pathway to target in HF management was natural to be considered.[5] </plain></SENT>
</text></p></sec><sec id="s3"><label>3</label><title><text><SENT sid="19" pm="."><plain>Neprilysin inhibition </plain></SENT>
</text></title><p><text><SENT sid="20" pm="."><plain>The clearance of NPs takes place by two different processes such as a receptor-mediated-degradation and an enzymatic breakdown mainly executed by a zinc-dependent metallopeptidase called, Neprilysin (NEP).[5] Therefore, suppressing the activity of this enzyme could be an attractive option to increase NPs levels.[6] </plain></SENT>
</text></p><p><text><SENT sid="21" pm="."><plain>NEP is widely expressed in mammals (kidneys, lungs, cardiac myocytes, vascular wall, etc) but it is not only responsible of NPs degradation because it also cleaves other several peptides with vasoconstrictor effects like angiotensin II (Ang-II) and endothelin-1, among others.[7],[8] In consequence, inhibition of NEP would increase circulating levels of NPs which in turn stimulate the synthesis of cGMP promoting natriuresis, diuresis and vasodilation (beneficial in HF),[5] but apart from this, it may increase levels of Ang-II whose over-activation contributes to vasoconstriction and sodium retention (harmful un HF).[1] Therefore, the benefits of increasing the NPs system may be lost by increasing Ang-II, so a simultaneous suppression of the RAAS is necessary. </plain></SENT>
<SENT sid="22" pm="."><plain>In consequence this fact gave a clear pharmacological justification for agents that block both, NEP and Ang-II.[6] </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>In this setting, different NEP inhibitors were clinically checked; candoxatril the first pure NEP inhibitor result a failure since it concomitantly promoted natriuresis (via ANP) and systemic and pulmonary vascular resistances increase (via Ang-II).[9] Ecadotril, a second agent but with similar mechanism of action was another failure because it showed no clinical benefits with a non-acceptable safety profile.[10] Further on, a combined inhibition (ACE and NEP) was considered but it resulted in another negative experience. </plain></SENT>
<SENT sid="24" pm="."><plain>In the OVERTURE trial (omapatrilat versus enalapril randomized trial of utility in reducing events) a target dose of enalapril (10 mg twice daily) was compared with omapatrilat, an ACE-NEP inhibitor (40 mg once daily) which was found not superior to enalapril regarding the primary composite endpoint (death from any cause or HF hospitalization). </plain></SENT>
<SENT sid="25" pm="."><plain>In addition, it was associated to a significant increase in angioedema favored by the augmented levels of bradykinin.[11],[12] </plain></SENT>
</text></p></sec><sec id="s4"><label>4</label><title><text><SENT sid="26" pm="."><plain>Angiotensin receptor blocker neprilysin inhibitors </plain></SENT>
</text></title><p><text><SENT sid="27" pm="."><plain>Next step in order to solve the failure of omapatrilat was the combination of an ARB and a NEP inhibitor. </plain></SENT>
<SENT sid="28" pm="."><plain>Sacubitril/valsartan (previously LCZ696) is a fused molecule that contains 1:1 molar ratio of sacubitril (prodrug), a NEP inhibitor and valsartan, an ARB. </plain></SENT>
</text></p><p><text><SENT sid="29" pm="."><plain>It is a first-in-class medicine (ARNI) specifically designed to inhibit NEP (increasing NPs concentration) and simultaneously blocking the adverse effects of RAAS and reducing bradykinin enhancement (Figure 1).[13] </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>During 2015, Sacubitril/valsartan was approved by the US Food and Drug Administration (FDA) to reduce the risk of cardiovascular (CV) death and HF hospitalization in patients with chronic HF (NYHA Class II-IV) and reduced ejection fraction (EF),[14] and a few months later, by the European Medicine Agency (EMA) with a similar indication; treatment of symptomatic chronic HF with reduced EF in adult patients.[15] </plain></SENT>
</text></p></sec><sec id="s5"><label>5</label><title><text><SENT sid="31" pm="."><plain>Pharmacokinetics </plain></SENT>
</text></title><p><text><SENT sid="32" pm="."><plain>After oral administration, the compound dissociates into sacubitril and valsartan. </plain></SENT>
<SENT sid="33" pm="."><plain>Sacubitril is a prodrug which is subsequently metabolized (by esterases) to LBQ657 which is the active form and since this metabolite does no inhibit aminopeptidase P, the risk of angioedema is minimized in comparison with omapatrilat. </plain></SENT>
<SENT sid="34" pm="."><plain>Peak plasma concentrations are reached between 1.5–2.2 h for valsartan, 0.5–1.1 h for sacubitril and 1.9–3.5 h in the case of LBQ657. </plain></SENT>
<SENT sid="35" pm="."><plain>Steady state levels are achieved in three days and concomitant administration with food does not alter Sacubitril/valsartan pharmacokinetics.[13] </plain></SENT>
</text></p><SecTag type="FIG"><fig id="jgc-13-11-914-g001" position="float"><label>Figure 1.</label><caption><title><text><SENT sid="36" pm="."><plain>Sacubitril/valsartan: mode of action. </plain></SENT>
</text></title><p><text><SENT sid="37" pm="."><plain>*: dual concomitant inhibition (NEP and AT-1 receptor); #: enhance the benefits of NPs effects. </plain></SENT>
<SENT sid="38" pm="."><plain>The benefits of increasing the NPs system (NEP inhibition) may be lost by increasing angiotensin II, so a simultaneous suppression of the RAAS is necessary a simultaneous NEP inhibition (LBQ657) and AT1 receptor blockade (valsartan) is needed in order to maintain all the favourable biological action of NPs while the harmful effects of angiotensin II are avoided. +: enhance the benefits of NPs effects; AT1: subtype 1 angiotensin receptor; NEP: Neprilysin; NPs: natriuretic peptides; RAAS: renin-angiotensin-aldosterone system. </plain></SENT>
</text></p></caption><graphic xlink:href="jgc-13-11-914-g001"/></fig></SecTag><p><text><SENT sid="39" pm="."><plain>More consistent findings after oral its intake are increased plasma and urine cGMP and a decrease of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (due to NEP inhibition) while blockade of AT1 receptor increases plasma renin activity, renin and Ang-II concentrations.[16] </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>Sacubitril/valsartan was also design to be prescribed twice daily in order to guarantee 24-h action and it is offered in tablets containing 24 mg of sacubitril and 26 mg of valsartan, 49 mg of sacubitril and 51 mg of valsartan and 97 mg of sacubitril and 103 mg of valsartan. </plain></SENT>
<SENT sid="41" pm="."><plain>Bioavailability of valsartan in this formulation is higher than valsartan given alone so 26 mg, 51 mg and 103 mg of valsartan in Sacubitril/valsartan are equivalent to 40 mg, 80 mg and 160 mg of valsartan in ordinary tablets. </plain></SENT>
<SENT sid="42" pm="."><plain>Sacubitril is principally eliminated in urine (52%–68%) while valsartan is mainly via feces (86%).[13] </plain></SENT>
</text></p></sec><sec id="s6"><label>6</label><title><text><SENT sid="43" pm="."><plain>Sacubitril/valsartan in HFrEF </plain></SENT>
</text></title><p><text><SENT sid="44" pm="."><plain>The Prospective Comparison of ARNI with ACEi to determine Impact on Global Mortality and Morbidity in Hart failure Trial (PARADIGM-HF) was a double-blind, randomized and controlled trial. </plain></SENT>
<SENT sid="45" pm="."><plain>Its main intention was to compare head-to-head the effects of Sacubitril/valsartan with enalapril in adult patients with HFrEF. </plain></SENT>
<SENT sid="46" pm="."><plain>The trial randomized 8442 patients (mean age 64 years and 22% female) to receive 10 mg twice daily of enalapril (n = 4212) or 200 mg twice daily of Sacubitril / valsartan (n = 4187) (Table 1). </plain></SENT>
</text></p><p><text><SENT sid="47" pm="."><plain>Inclusion criteria were NYHA functional class II-IV, previously treated with an ACEi or ARB (equivalent to at least 10 mg of enalapril), left ventricular ejection fraction (LVEF) ≤ 40% (≤ 35% by amendment) and raised NPs levels. </plain></SENT>
<SENT sid="48" pm="."><plain>Patients were required to have a plasma BNP level ≥ 150 pg/mL (or NT-proBNP ≥ 600 pg/mL) or, if they had been hospitalized for HF (within the previous 12 months), a BNP level ≥ 100 pg/mL (or NT-proBNP ≥ 400 pg/mL). </plain></SENT>
<SENT sid="49" pm="."><plain>Main exclusions included systolic blood pressure &lt; 100 mmHg (screening), hyperkalemia or an estimated glomerular filtration rate (eGFR) &lt; 30 mL/min per 1.73 m2. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="jgc-13-11-914-t01" position="float"><label>Table 1.</label><caption><title><text><SENT sid="50" pm="."><plain>PARADIGM-HF:characteristics of the patients at baseline.[17] </plain></SENT>
</text></title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="51" pm="."><plain>Characteristic </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="52" pm="."><plain>Sacubitril/valsartan (n = 4187) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="53" pm="."><plain>Enalapril (n = 4212) </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="54" pm="."><plain>Age, yrs / Female sex </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="55" pm="."><plain>63.8 ± 11.5 / 879 (21%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="56" pm="."><plain>63.8 ± 11.3 / 953 (22.6%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="57" pm="."><plain>SBP, mmHg / HR, beats/min </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="58" pm="."><plain>122 ± 15 / 72 ± 12 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="59" pm="."><plain>121 ± 15 / 73 ± 12 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>NYHA functional class, % </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="61" pm="."><plain>I, II, III, IV (4.3 / 71.6 / 23.1 / 0.8) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>I, II, III, IV (5.0 / 69.3 / 24.9 / 0.6) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>Cr - mg/dL / LVEF, % </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>1.13 ± 0.3 / 29.6 ± 6.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>1.12 ± 0.3 / 29.4 ± 6.3 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>Median BNP, pg/mL </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>255 (155–474) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>251 (153–465) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>Median NT-proBNP, pg/mL </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>1631 (8815–3154) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>1594 (886–3305) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>Ischemic cardiomyopathy </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>2506 (59.9%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>2530 (60.1%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>Atrial fibrillation </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>1517 (36.2%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>1574 (37.4%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>Hypertension / diabetes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>2969 (70.9%) / 1451 (34.7%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>2971 (70.5%) / 1456 (34.6%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>Hospitalization for HF </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>2607 (62.3%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>2667 (63.3%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>Pre-trial use ACEi or ARB, % </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>78%/22.2% </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>77.5%/22.9% </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>Beta blocker / MRA </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>93.1 / 54.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>92.9 / 57 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p><text><SENT sid="90" pm="."><plain>Data are presented as n (%), mean ± SD, or mean (IQR). </plain></SENT>
<SENT sid="91" pm="."><plain>In both groups white and black races were 66% and 5.1%, respectively. </plain></SENT>
<SENT sid="92" pm="."><plain>Body-mass indexes were 28.1 ± 5.5 Kg/m2 (Sacubitril/valsartan) and 28.2 ± 5.5 Kg/m2 (enalapril). </plain></SENT>
<SENT sid="93" pm="."><plain>Pre-use of implantable cardioverter-defibrillators or resynchronization devices were as follow (%): 14.9/7 (Sacubitril/valsartan), 14.7/6.7 (enalapril). </plain></SENT>
<SENT sid="94" pm="."><plain>ACEi: ngiotensin-converting enzyme inhibitors; ARB: angiotensin-receptor blockers; BNP: brain natriuretic peptide; Cr: serum creatinine; HF: heart failure; IQR: interquartile range; LVEF: left ventricular ejection fraction; MRAs: mineralocorticoid receptor antagonists; NT-proBNP: N-terminal pro–B-type natriuretic peptide; NYHA: New York Heart Association; SBP: systolic blood pressure. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="95" pm="."><plain>The trial consisted of a screening period; a single-blind run-in period (all patients received enalapril 10 mg twice daily); it was followed by an additional single-blind run in period during which all patients who tolerated enalapril received Sacubitril/valsartan (100 mg twice daily and then 200 mg twice daily); and finally, a double-blind treatment period in two study groups. </plain></SENT>
<SENT sid="96" pm="."><plain>The single dose of 200 mg delivers the equivalent of 160 mg of valsartan and mean ± SD administered doses of Sacubitril/valsartan and enalapril were 375 ± 71 mg and 18.9 ± 3.4 mg, respectively. </plain></SENT>
</text></p><p><text><SENT sid="97" pm="."><plain>Primary endpoint was a composite of death from CV causes or first hospitalization for heart failure (HFH) while secondary outcomes were time to death from any cause, change from baseline at 8 months in the Kansas City Cardiomyopathy Questionnaire (KCCQ), time to new onset of atrial fibrillation and time to first declination of renal function. </plain></SENT>
<SENT sid="98" pm="."><plain>The study was interrupted early (March 2014) due to an overwhelming performance in the Sacubitril / valsartan arm after a median follow-up of 27 months. </plain></SENT>
</text></p><p><text><SENT sid="99" pm="."><plain>At the time of trial stopping, 21.8% of the Sacubitril/valsartan group and 26.5% of the enalapril one had reached the primary endpoint (HR: 0.80; 95% CI: 0.73–0.87; P &lt; 0.001). </plain></SENT>
<SENT sid="100" pm="."><plain>Compared with patients randomized to enalapril, the use of Sacubitril/valsartan reduced the risk of death from any cause by 16% (P &lt; 0.001) and the risk of hospitalization from HF by 21% (P &lt; 0.001). </plain></SENT>
<SENT sid="101" pm="."><plain>Overall mortality was also lower in the Sacubitril/valsartan arm (17.0% vs. </plain></SENT>
<SENT sid="102" pm="."><plain>19.8%, HR: 0.84, 95% CI: 0.76–0.93, P &lt; 0.001). </plain></SENT>
<SENT sid="103" pm="."><plain>Regarding the KCCQ, its mean change from baseline to month 8 was a reduction of 2.99 points and 4.63 points in the Sacubitril/valsartan and enalapril arms, respectively (P = 0.001). </plain></SENT>
<SENT sid="104" pm="."><plain>New onset atrial fibrillation was detected in 84 patients in the Sacubitril/valsartan group and in 83 patients taking enalapril (P = 0.84) while protocol defined worsening renal function, affected 94 patients of the Sacubitril/valsartan group and 108 of the enalapril one (P = 0.28) (Table 2). </plain></SENT>
</text></p><p><text><SENT sid="105" pm="."><plain>During the run-in period, 2079 patients (12%) discontinued the study due to side effects (657 subjects in enalapril and 605 in Sacubitril/valsartan). </plain></SENT>
<SENT sid="106" pm="."><plain>Hypotension, cough, hyperkalemia and renal dysfunction were the more commons with a higher rate in the enalapril group. </plain></SENT>
<SENT sid="107" pm="."><plain>This 12% dropout is important to take into account because it implies a limit of PARADIGM-HF results generalization since only patients that tolerated the run-in period were randomized. </plain></SENT>
<SENT sid="108" pm="."><plain>During trial, the most common adverse event was symptomatic hypotension which was more present in the Sacubitril /valsartan group (14% vs. </plain></SENT>
<SENT sid="109" pm="."><plain>9.2%, P &lt; 0.001). </plain></SENT>
<SENT sid="110" pm="."><plain>Patients in the enalapril arm were more likely to have hyperkalemia (serum potassium ≥ 6.0 mmol/L; 5.6 vs. </plain></SENT>
<SENT sid="111" pm="."><plain>4.3%, P = 0.007), renal deterioration (creatinine level ≥ 2.5 mg/dL; 4.5% vs. </plain></SENT>
<SENT sid="112" pm="."><plain>3.3%, P = 0.007) and cough (14.3% vs. </plain></SENT>
<SENT sid="113" pm="."><plain>11.3%, P &lt; 0.001). </plain></SENT>
<SENT sid="114" pm="."><plain>A non-significative incidence of non-serous angioedema affected more patients taking Sacubitril/valsartan (P = 0.13). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="jgc-13-11-914-t02" position="float"><label>Table 2.</label><caption><title><text><SENT sid="115" pm="."><plain>PARADIGM-HF: primary and secondary outcomes.[17] </plain></SENT>
</text></title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="111*" align="left" span="1"/><col width="140*" align="center" span="1"/><col width="89*" align="center" span="1"/><col width="70*" align="center" span="1"/><col width="70*" align="center" span="1"/></colgroup><thead><tr><td rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>Outcomes </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>Sacubitril/valsartan (n = 4187) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>Enalapril (n = 4212) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>Hazard Ratio (95% CI) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>P value </plain></SENT>
</text></td></tr></thead><tbody><tr><td rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>Primary composite outcome </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>Death from CV cause / first HFH </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>914 (21.8%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>1117 (26.5%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>0.80 (0.73–0.87) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>&lt; 0,001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>Death from CV cause </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>558 (13.3%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>693 (16.5 %) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>0,80 (0.71–0.89) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>&lt; 0,001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>First HFH </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>537 (12.8%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>658 (15.6 %) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>0.79 (0.71–0.89) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>&lt; 0,001 </plain></SENT>
</text></td></tr><tr><td rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>Secondary outcomes </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>Death from any cause </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>711 (17%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>835 (19,8%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>0,84 (0,76–0,93) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>Change in KCCQ </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>−2.99 ± 0.36 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>−4.63 ± 0.36 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>1,64 (0.63–2.65) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>New-onset atrial fibrillation </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>84 (3.1%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>83 (3.1%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>0,97 (0.72–1.31) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>0.83 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>Renal function deterioration </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>94 (2.2%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>108 (2.6%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>0.86 (065–1.13) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>0.28 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="nt102"><p><text><SENT sid="158" pm="."><plain>Data are presented as n (%) or mean ± SD. </plain></SENT>
<SENT sid="159" pm="."><plain>KCCQ at 8 months: range from 0–100 (higher scores showing fewer limitations). </plain></SENT>
<SENT sid="160" pm="."><plain>Renal function declination was defines as end stage renal disease or a decrease ≥ 50% in the estimated glomerular filtration rate form the randomization value or a decrease &gt; 30 mL/min per 1.73 m2, to less than 60 mL/min per 1.73 m2. </plain></SENT>
<SENT sid="161" pm="."><plain>CV: cardiovascular; HFH: heart failure hospitalization; KCCQ: Kansas City Cardiomyopathy Questionnaire. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="162" pm="."><plain>Basically, PARADIGM-HF showed that over a median of 27 months, Sacubitril/valsartan led to a highly statically significant 20% reduction in the combined primary endpoint (CV death and HFH) and a 16% reduction in the risk of death for any cause.[17] </plain></SENT>
</text></p></sec><sec id="s7"><label>7</label><title><text><SENT sid="163" pm="."><plain>Analyses after PARADIGM-HF </plain></SENT>
</text></title><sec id="s7a"><label>7.1</label><title><text><SENT sid="164" pm="."><plain>Age </plain></SENT>
</text></title><p><text><SENT sid="165" pm="."><plain>Older patients in PARADIGM-HF were more often female, white (enrolled in Western Europe and North America) with higher systolic blood pressure and NPs levels. </plain></SENT>
<SENT sid="166" pm="."><plain>In addition, they were more likely to be in NYHA functional class III/IV than I/II with a worse renal function or to have ischemic heart disease or atrial fibrillation. </plain></SENT>
<SENT sid="167" pm="."><plain>Efficacy and safety outcomes according to age were examined in the following categories (years): &lt; 55 (n = 1624), 55–64 (n = 2655), 65–74 (n = 2655), and ≥ 75 (n = 1563) and even the above mentioned differences, the effect of Sacubitril/valsartan was similar across all the spectrums. </plain></SENT>
<SENT sid="168" pm="."><plain>Overall hazard ratio (HR) was 0.80 (95% CI: 0.73–0.87; P &lt; 0.001) and adverse events increased with age, being hypotension more frequent in patients taking Sacubitril/valsartan while renal impairment and hyperkalemia affected more the enalapril arm.[18] </plain></SENT>
</text></p></sec><sec id="s7b"><label>7.2</label><title><text><SENT sid="169" pm="."><plain>Geographical variation </plain></SENT>
</text></title><p><text><SENT sid="170" pm="."><plain>In PARADIGM-HF, 622 patients (8%) were recruited in North America (NA), 1680 (20%) in Western Europe (WE), 2762 (33%) in Central-Eastern Europe &amp; Russia (CEER), 1413 (17%) in Latin America (LA) and 1487 (18%) in Asia-Pacific (AP). </plain></SENT>
<SENT sid="171" pm="."><plain>There were as expected, many regional differences and more notable were: WE patients were about 10 years older than those from AP (68 vs. </plain></SENT>
<SENT sid="172" pm="."><plain>58 years) and women were more present in LA cohort than in the NA one (27% vs. </plain></SENT>
<SENT sid="173" pm="."><plain>17%). </plain></SENT>
<SENT sid="174" pm="."><plain>Coronary artery disease affected more NA patients (62%) than patients recruited in LA (43%). </plain></SENT>
</text></p><p><text><SENT sid="175" pm="."><plain>Patients from CEER, showed more hypertension (87%) and atrial fibrillation (52%) than those from AP (48% and 17%, respectively) but a eGFR &lt; 60 mL/min per 1.73 m2 was more frequent in NA patients (51%) than in those from AP ( 27%). </plain></SENT>
</text></p><p><text><SENT sid="176" pm="."><plain>In this wide and heterogeneous context, rates of the primary composite outcome (per 100 patient-years) varied among regions (from lowest to highest): WE 9.6 (95% CI: 8.6–10.6), LA 11.2 (10.0–12.5), 12.5 (11.3–13.8), CEER 12.3 (11.4–13.2) and NA 13.5 (11.7–15.6). </plain></SENT>
<SENT sid="177" pm="."><plain>After adjustment values (using NA as reference region), WE exhibited the lowest risk (HR 0.84, 95% CI: 0.70–1.01) vs. </plain></SENT>
<SENT sid="178" pm="."><plain>AP with the highest one (HR 1.36, 95% CI: 1.05–1.76). </plain></SENT>
<SENT sid="179" pm="."><plain>Risk of CV death was higher in LA and AP with a lowest risk for HFH in WE; hospitalization duration was shortest in NA and WE and longest in CEER. </plain></SENT>
<SENT sid="180" pm="."><plain>In any case and despite all these regional differences, the clinical benefit of Sacubitril / valsartan was not affected.[19] </plain></SENT>
</text></p></sec><sec id="s7c"><label>7.3</label><title><text><SENT sid="181" pm="."><plain>LVEF </plain></SENT>
</text></title><p><text><SENT sid="182" pm="."><plain>For analysis, LVEF was divided into the following categories: &lt; 17.5% (n = 339), ≥ 17.5% to &lt; 22.5% (n = 930), ≥ 22.5% to &lt; 27.5% (n = 1500), ≥ 27.5% to &lt; 32.5% (n = 2486) and ≥ 32.5% (n = 3143). </plain></SENT>
<SENT sid="183" pm="."><plain>Patients with lower EF were younger and more likely to be male and to be in NYHA functional class III/IV (than I/II) with a higher serum creatinine In addition, they were less likely to have history of hypertension, myocardial infarction, or atrial fibrillation. </plain></SENT>
<SENT sid="184" pm="."><plain>LVEF was documented as a significant and independent predictor of all outcome (risk increased with the decrease of LVEF); each 5-point in its reduction was associated with a 9% increased risk of the combined primary endpoint (HR: 1.09; 95% CI: 1.05–1.13; P &lt; 0.001), a 9% increased for CV death (HR:1.09; 95% CI: 1.04–1.14), a 9% increased risk in HFH (HR: 1.09; 95% CI: 1.04–1.14), and a 7% increased risk in all-cause mortality (HR: 1.07; 95% CI: 1.03–1.12). </plain></SENT>
<SENT sid="185" pm="."><plain>Sacubitril/valsartan was effective across the whole spectrum without any heterogeneity for the primary endpoint (Pinteraction = 0.87), CV death (Pinteraction = 0.55), HFH (Pinteraction = 0.78) and all cause mortality (Pinteraction = 0.93),[20] (Table 3). </plain></SENT>
</text></p></sec><sec id="s7d"><label>7.4</label><title><text><SENT sid="186" pm="."><plain>HF severity </plain></SENT>
</text></title><p><text><SENT sid="187" pm="."><plain>This analysis was done in order to examine the spectrum of risk in PARADIGM-HF and the effect of Sacubitril/valsartan across that spectrum. </plain></SENT>
<SENT sid="188" pm="."><plain>Baseline risk for each patient in PARADIGM-HF was calculated using the MAGGIC risk score (Meta-Analysis Global Group in Chronic Heart Failure) whose median value was 20 (IQR: 16 to 24). </plain></SENT>
<SENT sid="189" pm="."><plain>Each 1-point increase in score was associated with a 6% higher risk for the primary composite endpoint (P &lt; 0.001) and a 7% increased risk for CV death (P &lt; 0.001). </plain></SENT>
<SENT sid="190" pm="."><plain>The benefit of Sacubitril/valsartan was similar across the spectrum of risk (P = 0.159) although the absolute benefit was greater for patients at the highest risk. </plain></SENT>
<SENT sid="191" pm="."><plain>Treating 100 patients for two years with Sacubitril / valsartan as an alternative of enalapril led to seven fewer patients in the highest quintile of risk facing primary outcomes (compared with three in the lowest quintile).[21] </plain></SENT>
</text></p></sec><sec id="s7e"><label>7.5</label><title><text><SENT sid="192" pm="."><plain>Disease progression </plain></SENT>
</text></title><p><text><SENT sid="193" pm="."><plain>Sacubitril/valsartan was more effective than enalapril preventing clinical deterioration. </plain></SENT>
<SENT sid="194" pm="."><plain>Less patients in the Sacubitril/valsartan arm (vs. </plain></SENT>
<SENT sid="195" pm="."><plain>enalapril) required to intensify their HF treatment including, the need of intravenous positive inotropic support or the necessity to visit an emergency department due to worsening HF. </plain></SENT>
<SENT sid="196" pm="."><plain>In addition, patients treated with Sacubitril/valsartan were less likely to be hospitalized for HF (once or multiple times) and this diminution was already patent within the first 30 days after randomization (Table 4). </plain></SENT>
<SENT sid="197" pm="."><plain>Regarding biomarkers, patients treated with Sacubitril/valsartan had significantly lower levels of plasma NT-proBNP and troponin (as an expression myocardial wall stress and injury reduction) while levels of urinary cGMP and plasma BNP are increased (reflecting NEP inhibition).[22] </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="jgc-13-11-914-t03" position="float"><label>Table 3.</label><caption><title><text><SENT sid="198" pm="."><plain>PARADIGM-HF: outcomes incidence rates by LVEF (100 patient/year).[20] </plain></SENT>
</text></title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>Outcomes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>&lt; 17.5% (n = 339) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>17.5% 22.5% (n = 930) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>22.5%–27.5% (n = 1500) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>≥ 27.5%–32.5% (n = 2486) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>≤ 32.5% (n = 3143) </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>CV death/HFH </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>18.7 (15.6–24.5) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>15.2 (13.5–17.1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>13.2 (12.0–14.6) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>11.9 (10.9–12.9) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>9.7 (9.0–10.4) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>CV death </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>10.9 (8.6–13.6) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>9.1 (7.8–10.5) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>7.3 (6.4–8.3) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>6.8 (6.1–7.5) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>5.5 (5.0–6.1) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>HFH </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>11.9 (9.4–14.9) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>8.7 (7.5–10.2) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>7.6 (6.7–8.7) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>7.3 (6.6–8.1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>5.5 (5.0–6.1) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>All–cause death </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>12.5 (10.1–15.4) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>11.1 (9.7–12.6) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>8.6 (7.6–9.7) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>8.3 (7.6–9.1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>7.2 (6.6–7.8) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="nt103"><p><text><SENT sid="229" pm="."><plain>LVEF ranged from 5% to 42% (mean: 29.5% ± 6.2%) and echocardiography was the predominant method for assessment (96%). </plain></SENT>
<SENT sid="230" pm="."><plain>Median time between LVEF determination and screening was 27 days (range: 2–73). </plain></SENT>
<SENT sid="231" pm="."><plain>Incidence of all outcomes was greatest at the lower end of LVEF spectrum and patients in this situation were preferably younger (mostly men) and more likely to be in NYHA functional class III/IV (than I/II) showing lower systolic blood pressure and higher values of serum creatinine. </plain></SENT>
<SENT sid="232" pm="."><plain>CV: cardiovascular; HFH: heart failure hospitalization; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="jgc-13-11-914-t04" position="float"><label>Table 4.</label><caption><title><text><SENT sid="233" pm="."><plain>PARADIGM-HF: clinical progression of surviving patients.[22] </plain></SENT>
</text></title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>Nonfatal clinical deterioration: prespecified measures </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>Enalapril (n = 4212) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>Sacubitril/valsartan (n = 4187) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>HR (95% CI)/P Value </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>Outpatient therapy intensification </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>604 (14.3%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>520 (12.4%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>0.84 (0.74–0.94) / 0.003 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>ED visit for HF </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>150 (3.6%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>102 (2.4%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>0.66 (0.52–0.85) / 0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>Patients hospitalized for HF </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>658 (15.6%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>537 (12.8%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>0.79 (0.71–0.89) / &lt; 0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>HFH </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>1079 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>851 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>0.77 (0.67–0.89)*/ &lt; 0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>Patients receiving IV inotropic drugs </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>229 (5.4%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>161 (3.9%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>0.69 (0.57–0.85)/ &lt; 0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>Patients requiring CRT, VAD or HT </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>119 (2.8%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>94 (2.3%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>0.78 (0.60–1.02) / 0.07 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="nt104"><p><text><SENT sid="262" pm="."><plain>Data are presented as n (%) or n. *: rate ratio estimated from a negative binomial model; ratios without an asterisk are hazard ratios derived by using the Cox proportional hazards model. </plain></SENT>
<SENT sid="263" pm="."><plain>Sacubitril/valsartan prevented more efficiently clinical progression of surviving patients with heart failure than enalapril. </plain></SENT>
<SENT sid="264" pm="."><plain>In addition, it led an early and sustained reduction in biomarkers of both, myocardial wall stress and injury. </plain></SENT>
<SENT sid="265" pm="."><plain>CI: confidence interval; CRT: cardiac resynchronization therapy; ED: emergency department; HFH: heart failure hospitalization; HR: hazard ratio; HT: heart transplantation; IV: intravenous; VAD: ventricular assist device. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s7f"><label>7.6</label><title><text><SENT sid="266" pm="."><plain>Mode of death </plain></SENT>
</text></title><p><text><SENT sid="267" pm="."><plain>During the trial, 1546 patients died (all cause mortality) including 711 (17%) in the Sacubitril/valsartan arm and 833 patients (19.8 %) in the enalapril one (HR 0.84, 95% CI: 0.76–0.93). </plain></SENT>
<SENT sid="268" pm="."><plain>Majority of death (80.9%) were linked to CV causes with 558 cases in patients taking Sacubitril / valsartan (13.3%) and 693 (16.5%) in the enalapril group (HR 0.80; 95% CI: 0.72–0.89; P &lt; 0.001). </plain></SENT>
<SENT sid="269" pm="."><plain>Sudden death accounted for 44.8% of CV death while pump failure was considered in 26.5% and both, were reduced by Sacubitril/valsartan (vs. </plain></SENT>
<SENT sid="270" pm="."><plain>enalapril). </plain></SENT>
<SENT sid="271" pm="."><plain>Non-CV death and other causes of CV death like myocardial infarction or stroke did not differ between both groups (Figure 2).[23] </plain></SENT>
</text></p><p><text><SENT sid="272" pm="."><plain>The significant quantity of SD in PARADIGM-HF was relatively similar to other trials in which the majority of included patients had mild to moderate symptoms (V-HEFT II, MERIT HF, etc),[24],[25] while other trials that enrolled more severe patients, exhibited a larger proportion of death due to progressive HF (CONSENSUS, RALES).[26],[27] </plain></SENT>
</text></p></sec><sec id="s7g"><label>7.7</label><title><text><SENT sid="273" pm="."><plain>Lower vs. target doses </plain></SENT>
</text></title><p><text><SENT sid="274" pm="."><plain>In this intent to treat analysis, patients (n = 4850) who received the maximal dose (200 mg Sacubitril/valsartan or 10 mg enalapril twice daily) along the trial were compared with those (n = 35,649) who required any dose reduction to lower doses (100/50/0 mg of Sacubitril/valsartan and 5/2.5/0 mg of enalapril twice daily. </plain></SENT>
<SENT sid="275" pm="."><plain>A total of 43% in the enalapril arm and 42% in the Sacubitril/valsartan one reduced their dose at any time after randomization (median time to dose reduction were 255 days for enalapril and 249 days for Sacubitril/valsartan; P = 0.54). </plain></SENT>
<SENT sid="276" pm="."><plain>Subjects in both groups who needed a dose reduction were older, had worse NYHA functional class, higher serum creatinine levels and NT-proBNP values at baseline. </plain></SENT>
<SENT sid="277" pm="."><plain>In this context, any dose reduction regardless of treatment assignment was associated with a higher subsequent risk of the primary event (HR 2.5, 95% CI: 2.2–2.7). </plain></SENT>
<SENT sid="278" pm="."><plain>However, the treatment benefit of Sacubitril/valsartan over enalapril following a dose reduction was similar (HR 0.80, 95% CI: 0.70–0.93; P &lt; 0.001) to that observed in patients who had not experienced any dose of reduction (HR 0.79, 95% CI: 0.71–0.88; P &lt; 0.001). </plain></SENT>
<SENT sid="279" pm="."><plain>This analysis suggest that those patients who were unable to tolerate target doses of Sacubitril/valsartan or enalapril still benefited from lower doses of Sacubitril/valsartan in comparison with lower doses of enalapril.[28] </plain></SENT>
</text></p><SecTag type="FIG"><fig id="jgc-13-11-914-g002" position="float"><label>Figure 2.</label><caption><title><text><SENT sid="280" pm="."><plain>Causes and rates of death according to treatment in PARADIGM-HF. </plain></SENT>
</text></title><p><text><SENT sid="281" pm="."><plain>*Percentage of deaths. </plain></SENT>
<SENT sid="282" pm="."><plain>In PARADIGM-HF, the majority of cardiovascular deaths were categorized as sudden (44.8%) or heart failure related (26.5%) and in both cases, the hazard ratio was significantly reduced by Sacubitril/valsartan vs. enalapril. </plain></SENT>
<SENT sid="283" pm="."><plain>Deaths linked to other cardiovascular causes (myocardial infarction and stroke), were infrequent and distributed uniformly between both groups, as were non-cardiovascular deaths. </plain></SENT>
<SENT sid="284" pm="."><plain>HF: heart failure. </plain></SENT>
</text></p></caption><graphic xlink:href="jgc-13-11-914-g002"/></fig></SecTag></sec></sec><sec id="s8"><label>8</label><title><text><SENT sid="285" pm="."><plain>Place in therapy </plain></SENT>
</text></title><p><text><SENT sid="286" pm="."><plain>Less than a year after regulatory approvals, Sacubitril / valsartan got a strong class I recommendation in both, US and European HF guidelines (May, 2016). </plain></SENT>
<SENT sid="287" pm="."><plain>In the EU guidelines,[29] Sacubitril/valsartan obtained a recommendation IB which denotes class I (is recommended) and level of evidence B (data derived from one single trial). </plain></SENT>
<SENT sid="288" pm="."><plain>It implies that Sacubitril/valsartan is recommended as an ACEi replacement to further reduce the risk of HFH and death in ambulatory patients with HF and reduced EF who remains symptomatic (NYHA class II to IV) despite optimal treatment with an ACEI, a beta-blocker and an MRA. </plain></SENT>
<SENT sid="289" pm="."><plain>For European authors a reduced LVEF is ≤ 35% and values of BNP ≥ 150 pg/mL or NT-proBNP ≥ 600 pg/mL or BNP ≥ 100 pg/mL and NT-proBNP ≥ 400 pg/mL with a HFH in the previous year 12 months are helpful to make the decision. </plain></SENT>
</text></p><p><text><SENT sid="290" pm="."><plain>In the case of US guidelines,[30] Sacubitril/valsartan got a recommendation I-BR that signifies a class of recommendation I “strong” and level of evidence BR “moderate quality” (evidence based in only one study). </plain></SENT>
<SENT sid="291" pm="."><plain>In consequence, an ARNI should be recommended to further reduce morbidity and mortality in patients with chronic symptomatic HF, reduced EF, NYHA class II or III and who tolerate an ACEi or ARB (replacement). </plain></SENT>
<SENT sid="292" pm="."><plain>Therefore, Sacubitril/valsartan is integrated into the standard therapy for HF with reduced EF as an alternative to an ACEi or an ARB, given together with a beta blocker and an MRA. </plain></SENT>
<SENT sid="293" pm="."><plain>For US authors, there is not any specific cutting level of EF needed to indicate Sacubitril/valsartan (only reduced EF) and/or the necessity of a prior MRA utilization. </plain></SENT>
</text></p><p><text><SENT sid="294" pm="."><plain>In conclusion, key indications for Sacubitril/valsartan introduction seems to be patients with chronic NYHA class II to IV and reduced EF (≤ 35%) currently being treated with a beta blocker (at recommended target doses) and an ACEi (dose equivalent to 10 mg twice daily) or an ARB. </plain></SENT>
<SENT sid="295" pm="."><plain>A preferential treatment with an MRA can also be considered but taking into account that more than 40% of patients recruited in PARADIGM did not receive any MRA. </plain></SENT>
<SENT sid="296" pm="."><plain>An episode of HFH in the previous year and/or elevated values of BNP or NT-proBNP could be helpful. </plain></SENT>
</text></p></sec><sec id="s9"><label>9</label><title><text><SENT sid="297" pm="."><plain>Sacubitril/valsartan: dosing and cautions </plain></SENT>
</text></title><p><text><SENT sid="298" pm="."><plain>The recommended starting dose for HF treatment is Sacubitril/valsartan 49/51 mg twice a day (with or without food). </plain></SENT>
<SENT sid="299" pm="."><plain>This dose has to be doubled after a period of 2–4 weeks to Sacubitril/valsartan 97/103 mg twice daily (target maintenance dose). </plain></SENT>
<SENT sid="300" pm="."><plain>The starting dose should be reduced to Sacubitril/valsartan 24/26 mg twice daily for patients not currently taking an ACEi or an ARB or who were taking a low dose of these agents, for patients with severe renal impairment (GFR &lt; 30 mL/min per 1.73m2) and for patients with moderate hepatic insufficiency. </plain></SENT>
<SENT sid="301" pm="."><plain>Dose adjustment as required and tolerated by the patients has to be done in 2–4 weeks.[31] </plain></SENT>
</text></p><p><text><SENT sid="302" pm="."><plain>Renal function and serum potassium should be checked as for any other RAAS inhibitor or blocker. </plain></SENT>
<SENT sid="303" pm="."><plain>Sacubitril/valsartan is not recommended to be started in patients with a systolic blood pressure &lt; 100 mmHg or serum potassium levels &gt; 5.4 mmol/L. </plain></SENT>
<SENT sid="304" pm="."><plain>The necessity of adjusting the dosing of other agents (diuretics, antihypertensive drugs, etc) should be considered facing the development of hypotension, renal impairment or hyperkalemia. </plain></SENT>
<SENT sid="305" pm="."><plain>Sacubitril/valsartan utilization should be quickly stopped in case of angioedema appearance and it is very important to remark the total necessity of stopping any previous ACEi treatment for 36 h before initiating Sacubitril / valsartan.[31] </plain></SENT>
</text></p><p><text><SENT sid="306" pm="."><plain>Sacubitril/valsartan can cause fetal damage (as any drug acting on the RAAS system) so it is contraindicated in pregnancy and during lactation. </plain></SENT>
<SENT sid="307" pm="."><plain>Concurrent use with a potassium-sparring diuretic may increase serum potassium levels so if this association is needed, serum potassium levels should be checked regularly. </plain></SENT>
<SENT sid="308" pm="."><plain>Simultaneous utilization of Sacubitril/valsartan with non-steroidal anti-inflammatory drugs and lithium may increase the risk of renal failure development and lithium toxicity, respectively.[31] </plain></SENT>
</text></p><p><text><SENT sid="309" pm="."><plain>Finally, it is important to clarify that BNP is not an appropriate biomarker of HF severity in patients taking Sacubitril/valsartan since it is a NEP substrate; NT-proBNP is more useful since its levels are in this case, a real reflex of wall stress reduction.[32] </plain></SENT>
</text></p></sec><sec id="s10"><label>10</label><title><text><SENT sid="310" pm="."><plain>NEP inhibition: unaddressed issues </plain></SENT>
</text></title><p><text><SENT sid="311" pm="."><plain>There is a risk of angioedema with Sacubitril / valsartan and prior to its initiation; patients should discontinue therapy with an ACEi al least 36 hours before.[31] Black Americans have a natural increased risk of angioedema (ACEi associated)[33] and their presence in PARADIGM-HF population, were very low (5%).[17] </plain></SENT>
</text></p><p><text><SENT sid="312" pm="."><plain>There were 54 confirmed angioedema cases during PARADIGM-HF duration (run-in period 25 and double-blind period 29) with 25 events in the enalapril arm and 29 in the Sacubitril/valsartan one. </plain></SENT>
<SENT sid="313" pm="."><plain>The majority of events were of mild severity (no treatment or antihistamines) with only five patients (two enalapril, three Sacubitril/valsartan) requiring hospitalization (no mechanical airway support was needed). </plain></SENT>
<SENT sid="314" pm="."><plain>Regarding black patients, there were four cases (two Sacubitril/valsartan) within the 25 run-in confirmed angioedema ones and six cases (five Sacubitril/valsartan) in the 29 events during the randomization phase.[34] </plain></SENT>
</text></p><p><text><SENT sid="315" pm="."><plain>Therefore, it seems that black patients were at higher risk of angioedema events with both treatments so in order to assess if Sacubitril/valsartan is really safe in this population, an observational US study will be held in this kind of population.[35] In addition, this issue as well others (hypotension, hyperkalemia, renal impairment, hepatotoxicity, etc) will be addressed in a post-authorization European study focused in HF patients newly starting treatment with Sacubitril / valsartan.[35] </plain></SENT>
</text></p><p><text><SENT sid="316" pm="."><plain>Amyloid-β (Aβ) is generated in the brain through sequential cleavage of amyloid precursor protein (β and γ secretases),[36] and it is removed by multiple processes, including transport into cerebrospinal fluid, the bloodstream, and enzymatic degradation.[37] NEP is one of multiple enzymes degrading Aβ[38] so its inhibition by Sacubitril / valsartan may increase its levels with the consecutive brain accumulation. </plain></SENT>
<SENT sid="317" pm="."><plain>Senile plaques composed by Aβ aggregation are found in the brain of patients with Alzheimer's disease.[39] So in consequence, a theoretical risk may exist between Sacubitril/valsartan administration and Alzheimer's disease development. </plain></SENT>
</text></p><p><text><SENT sid="318" pm="."><plain>Although, no signals of an increase in dementia or cognitive impairment were seen in the PARADIGM-HF trial,[17] the effects of Sacubitril/valsartan on cognitive function will be assessed in the ongoing PARAGON-HF trial (NCT01920711)[35] In addition, a multicenter, randomized, double-blind, active-controlled study is planned in order to specifically evaluate cognitive impairment and brain amyloid plaque deposition (PET imaging) comparing Sacubitril/valsartan vs. valsartan.[35] </plain></SENT>
</text></p></sec><sec id="s11"><label>11</label><title><text><SENT sid="319" pm="."><plain>Sacubitril/valsartan in HF: looking ahead </plain></SENT>
</text></title><p><text><SENT sid="320" pm="."><plain>In the next years, clinical impact of Sacubitril/valsartan will be investigated in different HF scenarios like, preserved EF (NCT00887588), real life setting (NCT02690974), biomarkers (NCT02554890), pediatrics (NCT02678312), Japanese population (NCT02468232), ischemic functional mitral regurgitation (NCT02687932), post acute decompensation (NCT02661217) or asymptomatic patients with elevated natriuretic peptide and left atrial volume index (NCT02682719). </plain></SENT>
</text></p><p><text><SENT sid="321" pm="."><plain>In this context, the previously mentioned PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in Heart Failure with Preserved Ejection Fraction) has a transcendental importance since our current lack of proven clinical benefits in patients with HF and preserved EF. </plain></SENT>
<SENT sid="322" pm="."><plain>This trial is designed to compare the effects of Sacubitril/ valsartan and valsartan alone in reducing CV death or total HFH in patients with the following entry criteria: LVEF ≥ 45%, NYHA class II-IV, histories of HFH within 9 months or elevated NPs, and evidence of structural heart disease (left ventricular hypertrophy or left atrial enlargement) </plain></SENT>
</text></p><p><text><SENT sid="323" pm="."><plain>Therefore and considering PARADIGM results (largest HF trial ever) it seems that Sacubitril / valsartan has come to change the present and future cornerstone of HF treatment in all these different scenarios. </plain></SENT>
</text></p></sec><SecTag type="CONCL"><sec id="s12"><label>12</label><title><text><SENT sid="324" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="325" pm="."><plain>ACEi have been the cornerstone of HFrEF for more than 25 years since enalapril was found to improve survival.[26],[40] Sacubitril/valsartan represents a striking innovation in this field as an effective and safe alternative to ACEi because of its significant improvements in survival and reduced rates of HFH in comparison with enalapril. </plain></SENT>
<SENT sid="326" pm="."><plain>Hence and taking into account PARADIGM results, Sacubitril/valsartan can be considered over an ACEi or an ARB for the first-line management of patients with HFrEF. </plain></SENT>
<SENT sid="327" pm="."><plain>Very valuable information on different settings (real life, pediatrics, elderly, HF with preserved EF, acute decompensated HF, etc.) will be provided by planned and ongoing studies in the next years. </plain></SENT>
</text></p><p><text><SENT sid="328" pm="."><plain>In consequence, it is almost sure that our future daily clinical practice treating HF patients will be modified by a complete displacement of ACEi and ARBs in favor of Sacubitril/valsartan. </plain></SENT>
<SENT sid="329" pm="."><plain>Therefore, the hot question expressed in this same journal in 2015 “PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?”[41] has now a clear answer: “yes”. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="REF"><ref-list><title>References</title><ref id="b1"><text><SENT sid="330" pm="."><plain>1 GoldsmithSR Interactions between the sympathetic nervous system and the RAAS in heart failure Curr Heart Fail Rep 2004 1 45 50 16036024 </plain></SENT>
</text></ref><ref id="b2"><text><SENT sid="331" pm="."><plain>2 HuntSAAbrahamWTChinMH 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults Circulation 2009 119 e391 e479 19324966 </plain></SENT>
</text></ref><ref id="b3"><text><SENT sid="332" pm="."><plain>3 GoASMozaffarianDRogerVL Heart disease and stroke statistics–2013 update: a report from the American Heart Association Circulation 2013 127 143 152 23283859 </plain></SENT>
</text></ref><ref id="b4"><text><SENT sid="333" pm="."><plain>4 KrupickaJJanotaTKasalovaZ Natriuretic peptides – physiology, pathophysiology and clinical use in heart failure Physiol Res 2009 58 171 177 18380534 </plain></SENT>
</text></ref><ref id="b5"><text><SENT sid="334" pm="."><plain>5 VolpeMRubattuSBurnettJJr Natriuretic peptides in cardiovascular diseases: current use and perspectives Eur Heart J 2014 35 419 442 24227810 </plain></SENT>
</text></ref><ref id="b6"><text><SENT sid="335" pm="."><plain>6 VardenyOMillerRSolomonSD Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure JACC Heart Fail 2014 2 663 670 25306450 </plain></SENT>
</text></ref><ref id="b7"><text><SENT sid="336" pm="."><plain>7 ErdösEGSkidgelRA Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones FASEB J 1989 3 145 151 2521610 </plain></SENT>
</text></ref><ref id="b8"><text><SENT sid="337" pm="."><plain>8 Maguer-SattaVBesançonRBachelard-CascalesE Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer Stem Cells 2011 29 389 396 21425402 </plain></SENT>
</text></ref><ref id="b9"><text><SENT sid="338" pm="."><plain>9 KentschMOtterWDrummerC Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure Eur J Clin Pharmacol 1996 51 269 272 9010697 </plain></SENT>
</text></ref><ref id="b10"><text><SENT sid="339" pm="."><plain>10 ClelandJGSwedbergK Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure Lancet 1998 351 1657 1658 9620738 </plain></SENT>
</text></ref><ref id="b11"><text><SENT sid="340" pm="."><plain>11 PackerMCaliffRMKonstamMA Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation 2002 106 920 926 12186794 </plain></SENT>
</text></ref><ref id="b12"><text><SENT sid="341" pm="."><plain>12 FryerRMSegretiJBanforPN Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema Br J Pharmacol 2008 153 947 955 18084312 </plain></SENT>
</text></ref><ref id="b13"><text><SENT sid="342" pm="."><plain>13 GuJNoeAChandraP Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) J Clin Pharmacol 2010 50 401 414 19934029 </plain></SENT>
</text></ref><ref id="b14"><text><SENT sid="343" pm="."><plain>14 U.S. </plain></SENT>
<SENT sid="344" pm="."><plain>Department of Health and Human Services website <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncement/ucm453845.html">www.fda.gov/NewsEvents/Newsroom/PressAnnouncement/ucm453845.html</ext-link>. </plain></SENT>
<SENT sid="345" pm="."><plain>(Accessed July 7, 2015).  </plain></SENT>
</text></ref><ref id="b15"><text><SENT sid="346" pm="."><plain>15 New medicine to treat heart failure recommended for approval The European Medicines Agency website. <ext-link ext-link-type="uri" xlink:href="http://www.ema.europaeu/ema/index.jsp?curl=pages/news_and_events/news/2015/09/news_detail_002401.jsp&amp;mid=WC0b01ac058004d5c1">www.ema.europaeu/ema/index.jsp?curl=pages/news_and_events/news/2015/09/news_detail_002401.jsp&amp;mid=WC0b01ac058004d5c1</ext-link>. </plain></SENT>
<SENT sid="347" pm="."><plain>(Accessed Jan 16, 2016).  </plain></SENT>
</text></ref><ref id="b16"><text><SENT sid="348" pm="."><plain>16 KobalavaZAverkovOMerayI Natriuretic peptide inhibition in the presence of angiotensin receptor blockade following short term treatment with LCZ696 in heart failure patients: effect on ANP, BNP, NTproBNP and cGMP Eur Heart 2011 32(suppl) 784 785  </plain></SENT>
</text></ref><ref id="b17"><text><SENT sid="349" pm="."><plain>17 McMurrayJJPackerMDesaiAS Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 2014 371 993 1004 25176015 </plain></SENT>
</text></ref><ref id="b18"><text><SENT sid="350" pm="."><plain>18 JhundPSFuMBayramE Efficacy and safety of LCZ696 (sacubitril valsartan) according to age: insights from PARADIGM-HF Eur Heart J 2015 36 2576 2584 26231885 </plain></SENT>
</text></ref><ref id="b19"><text><SENT sid="351" pm="."><plain>19 KristensenSLMartinezFJhundPS Geographic variations in the PARADIGM-HF heart failure trial Eur Heart J Published Online First. </plain></SENT>
<SENT sid="352" pm="."><plain>28 Jun. </plain></SENT>
<SENT sid="353" pm="."><plain>2016. 10.1093/eurheartj/ehw326  </plain></SENT>
</text></ref><ref id="b20"><text><SENT sid="354" pm="."><plain>20 SolomonSDClaggettBDesaiAS Influence of ejection fraction on outcomes and efficacy of Sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction. </plain></SENT>
<SENT sid="355" pm="."><plain>The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial Circ Heart Fail 2016 9 e002744 26915374 </plain></SENT>
</text></ref><ref id="b21"><text><SENT sid="356" pm="."><plain>21 SimpsonJJhundPSSilva CardosoJ Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF J Am Coll Cardiol 2015 66 2059 2071 26541915 </plain></SENT>
</text></ref><ref id="b22"><text><SENT sid="357" pm="."><plain>22 PackerMMcMurrayJJDesaiAS Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure Circulation 2015 131 54 61 25403646 </plain></SENT>
</text></ref><ref id="b23"><text><SENT sid="358" pm="."><plain>23 DesaiASMcMurrayJJPackerM Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients Eur Heart J 2015 36 1990 1997 26022006 </plain></SENT>
</text></ref><ref id="b24"><text><SENT sid="359" pm="."><plain>24 CohnJNTognoniG A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure N Engl J Med 2001 345 1667 1675 11759645 </plain></SENT>
</text></ref><ref id="b25"><text><SENT sid="360" pm="."><plain>25 Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF) MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure Lancet 1999 353 2001 2007 10376614 </plain></SENT>
</text></ref><ref id="b26"><text><SENT sid="361" pm="."><plain>26 The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure N Engl J Med 1987 316 1429 1435 2883575 </plain></SENT>
</text></ref><ref id="b27"><text><SENT sid="362" pm="."><plain>27 PittBZannadFRemmeWJ The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 1999 341 709 717 10471456 </plain></SENT>
</text></ref><ref id="b28"><text><SENT sid="363" pm="."><plain>28 VardenyOClaggettBPackerM Efficacy of Sacubitril / valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial Eur J Heart Fail Published Online First. </plain></SENT>
<SENT sid="364" pm="."><plain>10 Jun. </plain></SENT>
<SENT sid="365" pm="."><plain>2016. 10.1002/ejhf.580  </plain></SENT>
</text></ref><ref id="b29"><text><SENT sid="366" pm="."><plain>29 PonikowskiPVoorsAAAnkerSD 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J Published Online First. </plain></SENT>
<SENT sid="367" pm="."><plain>20 May 2016. 10.1093/eurheartj/ehw128  </plain></SENT>
</text></ref><ref id="b30"><text><SENT sid="368" pm="."><plain>30 YancyCWJessupMBozkurtB 2016 ACC/AHA/ HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America J Am Coll Cardiol Published Online First. </plain></SENT>
<SENT sid="369" pm="."><plain>17 May 2016. 10.1016/j.jacc.2016.05.011  </plain></SENT>
</text></ref><ref id="b31"><text><SENT sid="370" pm="."><plain>31 CadaDJBakerDELeonardJ Sacubitril/Valsartan Hosp Pharm 2015 50 1025 1036 27621510 </plain></SENT>
</text></ref><ref id="b32"><text><SENT sid="371" pm="."><plain>32 MairJLindahlBGiannitsisE Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care? Eur Heart J Acute Cardiovasc Care Published Online First. </plain></SENT>
<SENT sid="372" pm="."><plain>Accessed pii: 2048872615626355  </plain></SENT>
</text></ref><ref id="b33"><text><SENT sid="373" pm="."><plain>33 BrownNJRayWASnowdenM Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema Clin Pharmacol Ther 1996 60 8 13 8689816 </plain></SENT>
</text></ref><ref id="b34"><text><SENT sid="374" pm="."><plain>34 KaplanAStreefkerkHThorburnC Comparison of angioedema in heart failure patients treated with Sacubitril / valsartan or enalapril in the PARADIGM-HF Study J Cardfail 2016 22  8 Suppl S66 S67  </plain></SENT>
</text></ref><ref id="b35"><text><SENT sid="375" pm="."><plain>35 EMASummary of the Risk Management Plan (RMP) for Entresto (Sacubitril/Valsartan) EMA website.<ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Risk-management-plan_summary/human/004062/WC500194315.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Risk-management-plan_summary/human/004062/WC500194315.pdf</ext-link>. </plain></SENT>
<SENT sid="376" pm="."><plain>(12 January 2016. </plain></SENT>
<SENT sid="377" pm="."><plain>July 24, 2016)  </plain></SENT>
</text></ref><ref id="b36"><text><SENT sid="378" pm="."><plain>36 HaassCKaetherCThinakaranG Trafficking and proteolytic processing of APP Cold Spring Harb Perspect Med 2012 2 a006270 22553493 </plain></SENT>
</text></ref><ref id="b37"><text><SENT sid="379" pm="."><plain>37 SaidoTLeissringMA Proteolytic degradation of amyloid β-protein Cold Spring Harb Perspect Med 2012 2 a006379 22675659 </plain></SENT>
</text></ref><ref id="b38"><text><SENT sid="380" pm="."><plain>38 TakakiYIwataNTsubukiS Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid β peptide in the brain J Biochem 2000 128 897 902 11098130 </plain></SENT>
</text></ref><ref id="b39"><text><SENT sid="381" pm="."><plain>39 HershLBRodgersDW Neprilysin and amyloid beta peptide degradation Curr Alzheimer Res 2008 5 225 231 18393807 </plain></SENT>
</text></ref><ref id="b40"><text><SENT sid="382" pm="."><plain>40 The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 1991 325 293 302 2057034 </plain></SENT>
</text></ref><ref id="b41"><text><SENT sid="383" pm="."><plain>41 KaplinskyE PARADIGM-HF Trial: will LCZ696 change the current treatment of systolic heart failure? J Geriatr Cardiol 2015 12 470 473 26512236 </plain></SENT>
</text></ref></ref-list></SecTag></back></article><?Pub *0000075232?>
